Neither use of bevacizumab, location of the primary tumor in the rectum, or metastatic disease burden were associated with increased intervention rate.
是否使用贝伐单抗、原发肿瘤的位置以及转移病灶的负荷均与干预措施的频率无关。
Neither use of bevacizumab, location of the primary tumor in the rectum, or metastatic disease burden were associated with increased intervention rate.
是否使用贝伐单抗、原发肿瘤的位置以及转移病灶的负荷均与干预措施的频率无关。
应用推荐